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Abstract
Recent advances in the understanding of the genetics of type 2 diabetes (T2D) susceptibility have focused attention on the
regulation of transcriptional activity within the pancreatic beta-cell. MicroRNAs (miRNAs) represent an important
component of regulatory control, and have proven roles in the development of human disease and control of glucose
homeostasis. We set out to establish the miRNA profile of human pancreatic islets and of enriched beta-cell populations,
and to explore their potential involvement in T2D susceptibility. We used Illumina small RNA sequencing to profile the
miRNA fraction in three preparations each of primary human islets and of enriched beta-cells generated by fluorescence-
activated cell sorting. In total, 366 miRNAs were found to be expressed (i.e..100 cumulative reads) in islets and 346 in beta-
cells; of the total of 384 unique miRNAs, 328 were shared. A comparison of the islet-cell miRNA profile with those of 15 other
human tissues identified 40 miRNAs predominantly expressed (i.e. .50% of all reads seen across the tissues) in islets.
Several highly-expressed islet miRNAs, such as miR-375, have established roles in the regulation of islet function, but others
(e.g. miR-27b-3p, miR-192-5p) have not previously been described in the context of islet biology. As a first step towards
exploring the role of islet-expressed miRNAs and their predicted mRNA targets in T2D pathogenesis, we looked at published
T2D association signals across these sites. We found evidence that predicted mRNA targets of islet-expressed miRNAs were
globally enriched for signals of T2D association (p-values ,0.01, q-values ,0.1). At six loci with genome-wide evidence for
T2D association (AP3S2, KCNK16, NOTCH2, SCL30A8, VPS26A, and WFS1) predicted mRNA target sites for islet-expressed
miRNAs overlapped potentially causal variants. In conclusion, we have described the miRNA profile of human islets and
beta-cells and provide evidence linking islet miRNAs to T2D pathogenesis.
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Introduction
The overwhelming majority of the disease-associated variation
identified by genome-wide association studies (GWAS) maps to the
non-protein-coding genome. Efforts to unlock the functional
impact of these variants therefore rely on an understanding of
the processes involved in the regulation of transcription, most
particularly those which are active in the cells and tissues
implicated in disease pathogenesis [1,2].
miRNAs, short (,22 nucleotides) non-coding RNAs, are
thought to play a key role in the regulation of cellular function
through effects on mRNA destabilisation and/or translational
repression [3,4]. Altered miRNA function has been implicated in
the pathogenesis of a growing number of diseases, including
Tourette’s syndrome and a variety of cancers [5,6]. There is also
substantial evidence linking miRNAs to the regulation of glucose
homeostasis. For example, miR-375 has been reproducibly shown
to be involved in the regulation of glucose-stimulated insulin
secretion in the murine insulin-secreting cell-line MIN6 [7,8] and
other miRNAs (let-7, miR-103 and -107) influence insulin
sensitivity in rodents [9,10].
Many of the variants robustly associated with type 2 diabetes
(T2D) in GWAS exert their diabetogenic effect via a primary
reduction in insulin secretion, placing the pancreatic islet, and the
insulin-secreting beta-cell in particular, center-stage in terms of
T2D pathogenesis [11]. Given significant differences in islet
physiology between rodents and humans [12], and with few
suitable human beta-cell lines available [13], the genomic
characterisation of primary human islet preparations provides an
important opportunity to develop the functional annotations that
can support biological inference at T2D association signals.
In this study, we set out to define the miRNA profile of primary
human islets and enriched human beta-cell preparations, and to
relate these findings to patterns of T2D predisposition.
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Results
The miRNA profile of human pancreatic islets and beta-
cells
Human islets were acquired from six donors with appropriate
ethical consent. For three of these samples the islets were subjected
to fluorescence-activated cell sorting (FACS) to select for beta-cells.
The purity of the beta-cells following FACS ranged between 90–
95%, and we refer to these as ‘‘enriched beta-cell’’ preparations.
All six samples (3 islet and 3 enriched beta-cells; see Table S1 for
clinical characteristics) were sequenced using 50 base pair reads on
either Illumina GAIIx or Hiseq2000 platforms. After quality
control, a total of 83 million reads mapping to small RNA species
were obtained across the three islet samples (648,000, 14 million,
68 million per sample), and 68 million across the enriched beta-
cell samples (3 million, 38 million, 26 million per sample). The
differences in read-depths reflect improvements in sequencing
technology over the period of data collection.
Almost all reads (92%) mapped to mature miRNA sequences
annotated in miRBase v18 [14], the remainder being snoRNAs
(2.4%) and other non-coding species in Ensembl v63 [15]. As the
number of annotated human miRNAs is still expanding, we used
the miRDeep2 package – a probabilistic method for discovering
miRNAs from small RNA sequencing data using the predicted
secondary structure of potential miRNA precursors [16] – to
uncover novel, unannotated miRNAs in our sequencing data, but
there were no instances of high confidence predictions of novel
miRNAs.
In islets, 366 miRNAs were expressed above background levels
(i.e. more than 100 combined reads across the three samples), and
346 in enriched beta-cells (Figure 1; Table S2). In total, 384
unique miRNAs were identified, of which 85% (n= 328) were
shared between islets and beta-cells (Table S2). The expression
profile was of medium complexity with on average 38 miRNAs
responsible for 90% of the total miRNA aligned reads in islets, and
21 in enriched beta-cells. There was good reproducibility across
the three samples of each type (Spearman rho range 0.61–0.96),
with all but one expressed miRNA present in at least two samples
of each type.
Several of the most highly expressed miRNAs in human islets
(including miR-375, miR-7-5p, miR-148a-3p, miR-26a-5p and
miR-127-3p) have been previously described in rodent or human
islets [7,17–20]. The expression in islets of others (e.g. miR-27b-
3p, miR-192-5p) is novel. Other islet-expressed miRNAs such as
miR-143-3p and let-7 family members have been implicated in
glucose homeostasis, but primarily in the context of insulin action
rather than insulin secretion [10,21,22].
Comparison of the miRNA expression profiles of islets and
enriched beta-cells revealed a strong correlation between the two
(Figure 1), but highlighted some interesting differences. For
example, amongst the most highly expressed miRNAs, miR-375
shows substantially higher abundance in enriched beta-cells as
compared to islets (42% vs 27%) whilst the opposite is true for
miR-143-3p (2% vs 16%). On the basis that an average islet
contains ,50% beta-cells [23], and, given an estimated 90%
purity of the FACS-enriched beta-cell preparations, the ,1.5 fold
enrichment of miR-375 in beta-cells compared to islets indicates
that, in human as in rodents [7], this miRNA is predominantly
expressed in beta-cells. On the same grounds, these data suggest
that miR-143-3p is mostly expressed outside pancreatic beta-cells.
Tissue specificity of miRNA expression
We compared the miRNA expression profiles in islets against
equivalent, publicly available, next-generation sequencing-derived
miRNA expression data from other human tissues, including B-
cells [24], liver [25], pigment cells [26], pooled thymocytes, bone
marrow, CD34+ progenitor cells [27], skin [28], lung, kidney,
skeletal muscle, heart, whole pancreas, frontal orbital gyrus,
spleen, liver tissue [29], and adipose tissue [30]. Raw reads were
downloaded, realigned and normalized in parallel with our islet
and beta-cell samples (see Methods). From these data, we
generated a tissue specificity score (see Methods), defined as the
expression of a miRNA in the reference tissue divided by the sum
of its expression in all tissues, and considered a value .0.5 to
indicate tissue-specificity.
By this definition (which indicated that half or more of all
observed reads for that miRNA were derived from islets) 40 of the
366 islet miRNAs were islet-specific (Table S3). Equivalent
specificity analyses using other tissues as reference found a mean
of only 10 enriched miRNAs per tissue (ranging from 1 [in spleen,
kidney and lung] to 31 [orbital gyrus]; Table S3). Inevitably, these
comparisons are influenced by the panel of tissues for which data
were available, but they suggest that the miRNA profile of human
islets is relatively distinct (Figure 2A). By permuting the data, we
estimated that the false-discovery rate associated with an assertion
of tissue specificity for a given miRNA was approximately 8%.
Few of the 10 most islet-specific miRNAs (Figure 2B; all with
specificity scores .0.8) have previously been implicated in islet
function. For miR-184, miR-182-5p and miR-127-3p, there is
published evidence for a role in insulin biosynthesis and secretion,
though for miR-184 and miR-127-3p this is restricted to
a correlation between islet expression levels and glucose-stimulated
insulin secretion [17,18]. For other miRNA transcripts, such as
miR-409-5p and miR-183-5p, the high degree of islet-specificity
may point to novel roles in the development and maintenance of
islet cellular phenotype.
Primary miRNA sequences tend to cluster together in genomic
intervals spanning,10 kb, and it is thought that members of these
clusters are transcribed together [30,31]. We found examples of
such clustering amongst the miRNAs showing the greatest
absolute abundance in islets, as well as those that were most
islet-specific. For example, mir-182 and mir-183 (both amongst the
most islet-specific transcripts) originate from the same cluster on
chromosome 7q32.2, whilst mir-136 and mir-127 map together on
chromosome 14q32.2. Across samples, expression levels of
miRNAs within these clusters are highly correlated both in islets
and enriched beta-cells (r2.0.6).
The role of islet-expressed miRNAs in T2D predisposition
To explore the role in T2D predisposition played by genetic
variants that influence miRNA function and/or expression, we
analysed genome-wide association data from 8,130 T2D cases and
38,987 controls available through the Diabetes Genetics Replica-
tion and Meta-analysis (DIAGRAM) consortium [11].
We first looked for evidence that T2D-associated variants
mapped to sequences encoding miRNAs themselves. Of the
,2.5 million variants for which directly-typed or HapMap-
imputed T2D-association p-values were available, seven over-
lapped precursor miRNA transcripts for islet-expressed mature
miRNAs (there were a total of 364 of these in miRBase v18
corresponding to the 366 mature miRNAs we document in islets).
Next, we asked whether the predicted targets of islet-expressed
miRNAs were enriched for evidence of association with T2D. To
determine whether results were robust to different algorithms for
predicting these target sites, we used three different prediction
algorithms (TargetScan, miRanda and miRDB) [32–34]. As two
of these algorithms (TargetScan and miRanda) provide genomic
coordinates for the target sites they predict, we were able, for
Islet miRNAs and T2D Pathogenesis
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these, to consider both the target genes and these specific target
sites. Looking at the predicted target sites of those 366 islet
miRNAs (a total of 39,103 and 749,873 such target sites were
predicted by TargetScan and miRanda respectively), we identified
6,496 variants overlapping the association data. The relatively low
density of common variants observed in both islet miRNA and
miRNA target sequence, is consistent with the constraints imposed
by negative selection [19,35,36]. Of the 6,503 variants overlapping
miRNA transcripts and predicted miRNA target sites, one variant,
rs3802177 at the SLC30A8 locus (p-value = 1.4561028) showed
genome-wide significant association for T2D in the DIAGRAM
meta-analysis data.
We also sought overlap with miRNA sequence and/or
predicted targets within the set of 58 loci for which there was
consistent evidence for genome-wide significant associations with
T2D (as of July 2012 [11,37,38]). As the causal variant at most
T2D-association loci is not known, we defined a broad set of 1,403
variants comprising the lead SNPs at the 58 loci plus all good
proxies (LD; r2.0.8 in CEU 1000 Genomes pilot data) which was
likely to include the alleles causal for these associations. We found
overlap of target sites (all predicted by miRanda) at ten of these
variants, mapping to six independent loci (AP3S2, KCNK16,
NOTCH2, SLC30A8, VPS26A, and WFS1).
Finally, we implemented an approach where we sought
evidence for enrichment of T2D association signals across sets of
islet-expressed genes predicted to be targeted by an individual
islet-expressed miRNA. As we used three different target pre-
diction algorithms, with often differing predicted target genes for
individual miRNAs, we looked at the degree of enrichment of
signal in the target genes predicted by each method alone, or by
the overlap (Figure 3). To test for enrichment within the predicted
transcriptional targets of each miRNA, we employed MAGENTA
[39], a tool that uses meta-analysis summary statistics to determine
enrichment for trait association across a given gene set while
correcting for differences in transcript size, number of variants,
and patterns of LD. We found significant enrichment (p-values
,0.01, q-value ,0.1) across islet miRNA targeted gene sets with
nearly all of the (combinations of) prediction algorithms used, with
significant enrichment (miR-17-5p, p-value = 0.004, q-val-
ue = 0.09; miR-93-5p, p-value = 0.005, q-value = 0.09; miR-20a-
5p, p-value = 0.009, q-value = 0.09) even in the set of targets
predicted by all three different algorithms (Figure 3, Table S4).
Discussion
Using next-generation sequencing, we have established the first
catalog of miRNAs in human pancreatic islets and beta-cells, and
explored the overlap between these miRNAs and T2D genetic
susceptibility. Our catalog not only serves as a valuable resource
for those interested in the roles of specific miRNAs in normal islet
physiology and beta-cell function, it also provides a reference for
the study of miRNA mediated abnormalities in islets from type 2
diabetic donors.
Figure 1. Islet and beta-cell miRNA profiles. The top 10 most abundant miRNAs in islets and beta-cells are annotated, with colors denoting
those shared between the two top 10s (black), in islet top 10 only (orange), and in beta-cell top 10 only (green). There was good correlation between
the two profiles (r2 = 0.78). A black dashed line represents equality.
doi:10.1371/journal.pone.0055272.g001
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The abundance of miR-375 in the miRNA profile provides
valuable support for a critical role in human pancreatic beta-cells,
mirroring the well-established role in rodent islet biology. miR-375
null mice are hyperglycaemic and exhibit reduced beta-cell mass
[40]. In a clonal rodent beta-cell line (MIN6), knockdown or over-
expression of this miRNA influences glucose-stimulated insulin
secretion [7]. Furthermore, knockdown of miR-375 in obese ob/
ob mice results in a more profound effect on glycaemia leading to
a severe diabetic phenotype in these mice [40]. Our study
establishes that miR-375 is also abundantly expressed in human
islets and warrants further studies to define the contribution of
miR-375 to the pathogenesis of T2D.
Most of the other abundant miRNAs show comparable levels of
expression between islets and beta-cells, and the islet-cell profiles
are relatively distinct from most of the other tissues studied. Our
data adds support for an islet-enriched expression pattern of six
miRNAs previously highlighted by microarray studies (miR-184,
miR-183-5p, miR-7-5p, miR-127-3p, miR-375, and miR-493-5p)
[17,20]. However, for many of the miRNAs that are most
abundant and/or enriched in human islets, there is little, if any,
existing data concerning their effects on islet development or
function. For example, these data point to the need to further
functional investigation of the let-7 family of miRNAs. Two recent
studies have demonstrated that manipulation of let-7 levels in
mice, by overexpression or knockdown, alters insulin sensitivity
[10,22]. One of these studies however also showed reduced insulin
secretion during an intraperitoneal glucose tolerance test in the let-
7 overexpressing mice, hinting at a role for let-7 in glucose-
stimulated insulin secretion, but did not characterize the effects of
altered let-7 expression on pancreatic islet physiology [22].
When we investigated the overlap between the islet miRNAs
and published T2D genome-wide association data, we found
evidence suggestive of a role for miRNAs in diabetes pathogenesis.
We identified both global enrichment of T2D association signals
within islet-expressed miRNA target genes, and overlap of
potentially causal T2D-associated variants with predicted target
sites for islet-expressed miRNAs.
Figure 2. Comparison of miRNA profiles across tissues. The left panel (A) shows the single-linkage hierarchical clustering of inter-tissue profile
correlations. In the right panel (B) the top 10 most tissue specific islet miRNAs are displayed in descending order. The colors indicate the normalized
expression levels of these miRNAs across the different profiles used in the analysis.
doi:10.1371/journal.pone.0055272.g002
Figure 3. Results for the T2D association signal enrichment
analysis in miRNA target gene sets. The Venn diagram represents
the sets of miRNA target genes for each miRNA as predicted by miRDB,
miRanda and TargetScan alone, or overlap of these methods.
Annotated are the median number of genes in each set (black text),
the number of significantly (p-value ,0.001, q-value ,0.1) enriched
gene sets (green text), and the median enrichment of the significantly
enriched gene sets (purple text).
doi:10.1371/journal.pone.0055272.g003
Islet miRNAs and T2D Pathogenesis
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The strongest signal of overlap we identified was for a variant
(rs3802177) within the 39 UTR of the SLC30A8 gene, which maps
to miRanda predicted target sites for six islet-expressed miRNAs
(miR-363-3p, miR-25-3p, miR-32-5p, miR-92a-3p, miR-33a-5p,
and miR-33b-5p) and reaches genome wide significance in T2D-
association studies [11]. Whilst, in the DIAGRAM meta-analysis,
rs3802177 is the variant with the strongest association with T2D
[11], it is also in complete linkage disequilibrium with a non-
synonymous coding variant in SLC30A8 (rs13266634), which is
generally considered to be the causal allele [41,42]. Further
functional studies will be required to establish whether rs3802177
could be contributing to perturbation of SLC30A8 expression
and/or function.
These data are based on the common variant associations
hitherto accessible to interrogation by GWAS. Extension of risk
variant discovery efforts through next-generation sequencing to
include low frequency and rare alleles will allow a more complete
evaluation of the role of miRNAs and their targets with respect to
pancreatic islet development and/or function and the pathogenesis
of T2D.
Materials and Methods
Samples
Human islets were obtained (with research consent) from the
Oxford DRWF Human Islet Isolation Facility (n = 4) and through
existing collaborations with Barcelona (n = 2) from deceased
donors of European descent (clinical characteristics of the donors
can be found in Table S1). High islet purity was established both
by dithizone labeling, as well as through comparative quantifica-
tion by qRT-PCR of endocrine (insulin [INS], glucagon [GCG],
somatostatin [SST]) and exocrine (pancreatic lipase [PNLIP],
pancreatic amylase [AMY2A] and chymotrypsin C [CTRC])
markers.
The beta-cell enriched preparation was collected through
fluorescence-activated cell sorting of human islet preparations
using a previously described method [43,44]. RNA was extracted
from all samples using TRI reagent (Applied Biosystems,
Warrington, UK).
Library preparation and sequencing
Only samples with a total RNA yield in excess of 1ug and
a quality score (RIN) .7 were selected for library preparation.
Libraries were prepared at the High-Throughput Genomics group
(Wellcome Trust Centre for Human Genetics, University of
Oxford, Oxford, UK) using Illumina v1.5 (2 islets and 1 beta-cell
sample) or TruSeq v1 (2 beta-cell and 1 islet sample) small library
preparation protocols, and sequenced using 50 base reads on
Illumina GAIIx and HiSeq2000 platforms respectively.
Raw sequence processing
Raw data was obtained in Fastq format, and pre-processed to
remove residual 39-adaptor sequences using the fastx_clipper
function from the FASTX-toolkit (http://hannonlab.cshl.edu/
fastx_toolkit/index.html). Sequences less than 16 bases after
adaptor stripping, and reads containing primarily N bases, were
removed. The remaining read sequences should correspond to
short RNAs. Length histograms showed enrichment of a peak
around 22 bases, which corresponds to the expected size of
miRNAs.
Sequence mapping and quantification
As ambiguities in read mapping, and frequent contamination by
large numbers of adaptor dimers pose significant challenges to the
accurate quantification of small RNAs, we used a three step
alignment approach. Reads were aligned using novoalign v.
2.07.11 (http://www.novocraft.com, parameters -h 60 60 -t30 -s -
m -l 16 -R 0 -r A 30), which is aware of sequence ambiguities, to
three consecutive references:
1. Contaminating sequences of adaptors, linkers, adaptor-linker,
and adaptor-tag combinations.
2. Full-length miRBase v17 hairpin sequences, combined with
other known and predicted human small RNA sequences
present in Ensembl v63 [14,15].
3. Human reference genome (NCBI build 37).
Reads mapping to contaminating sequences were excluded.
The remaining reads were prioritised in order miRNA . ncRNA
. genome, and alignments with the smallest edit distance were
selected. miRNA hairpin aligning reads were further split out into
mature miRNAs, star miRNAs and those reads mapping only to
the hairpin by using the respective coordinates on the hairpin from
miRBase v17 extended by 3 bases either side of the mature and
star sequences.
Finally, expression levels of each ncRNA were quantified by
counting the number of reads aligning to it. In case of multiple
mapping, where a read mapped between k alternative sequences in
one reference, 1/k was added to the count of each. Those RNA
sequences observed less than 100 times across all samples were
excluded. This cut-off was chosen as the reproducibility across
samples dropped when going lower, and means that per sample
.95% of all mapped sequences are included in the analysis.
Normalization
Data was normalized to be able to compare read counts
between samples, which all differ in read depth. An inflation factor
i was calculated for each library l using a method proposed by
Anders and Huber [45]. This was determined as the median
inflation factor across all genes g using the following formula: il =
mediang(ngl/GMl(ngl)), where ngl is the read count each gene g in
that library l, and GM is the geometric mean. Next, the data was
log2-transformed (log2(ngl/il)) to to account for the heteroskedastic
distribution of the data. These values were used in all subsequent
analyses.
Tissue specific analysis
Publicly available human small RNA sequencing data using
Illumina technology from B-cells [24], liver [25], pigment cells
[26], pooled thymocytes, bone marrow, CD34+ progenitor cells
[27], skin [28], lung, kidney, skeletal muscle, heart, pancreas,
frontal orbital gyrus, spleen, and liver tissue [29], as well as to data
from adipose tissue available through collaboration with the
MuTHER consortium [30], were downloaded, realigned and
normalized together with the islet and beta-cell samples. To
minimalize background, only those miRNAs observed at least
1000 times across the normalized values (n = 367) were taken
forward for tissue specific analysis.
Subsequently we calculated a tissue specificity score, defined as
the expression of a miRNA in a tissue divided by the sum of its
expression in all tissues, for each miRNA in each tissue. The
resulting fractional expression is an indicator of what proportion of
the expression of that miRNA is attributable to a given tissue. As
this approach would be limited in a set of tissues containing very
similar profiles, we combined the results from the islets and the
beta-cells and calculated a correlation matrix between the different
profiles and subjected this to single-linkage hierarchical clustering
in R version 2.14.0 using hclust [46]. To create profiles as unrelated
Islet miRNAs and T2D Pathogenesis
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as possible, all tissues with a Euclidian distance ,0.25 were
averaged along their branch. For each of the remaining 11
profiles, tissue specific scores were calculated by dividing the
normalized reads for a miRNA in a tissue by all reads in all tissue
for that miRNA. The resulting score thus represented the fraction
of miRNA reads explained by that tissue. Tissue-specificity was
defined by a score .0.5, which, using a permutation-based
approach comprising 1 million permutations of the observed data,
amounts to a false-discovery rate of 8%.
Involvement of miRNAs in T2D association
For all reported T2D loci, variants in strong LD (R2.0.8) in
1000 Genomes pilot CEU data were combined with the reported
T2D most associated variants using custom scripts. Genomic
locations of miRNAs were downloaded from miRBase v18
(http://www.mirbase.org) [14], Targetscan 6.2 [32] conserved
predictions from http://www.targetscan.org, miRanda predicted
targets with good mirSVR scores (release August 2010) [33] from
http://www.microrna.org/microrna/getDownloads.do and
miRDB (version 4) [34] predicted target genes from http://
mirdb.org/miRDB/download.html.
For the overlap with T2D associated variants, genomic
coordinates were, where appropriate, converted to hg18 using
the UCSC liftOver tool with -minMatch = 1. For the enrichment
analysis we determined the intersection between predicted islet-
expressed target genes of all three algorithms for each miRNA
using custom Perl scripts. MAGENTA [39] was run using pre-
defined settings using 100000 permutations for the p-value
calculation, and the 75th percentile cut-off p-values for establishing
enrichment. To correct for multiple testing q-values, which
represent the expected proportion of false positives incurred when
calling that gene set significant, were calculated using the qvalue
command from the package ‘‘qvalue’’ in R version 2.14.0 [46]
with the setting ‘‘robust =TRUE’’. Those gene sets with p-values
,0.01 and q-values ,0.1 were deemed significant.
Accession numbers
Datasets have been deposited in Gene Expression Omnibus
GEO (In process).
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